{"id":"W4224138250","doi":"10.1182/bloodadvances.2021006434","title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia ","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Pharmacyclics","keywords":"Ibrutinib; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Internal medicine; Hazard ratio; Adverse effect; Oncology; Confidence interval; Leukemia; Gastroenterology; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001556672,0.0004076912,0.0006515599,0.0001835913,0.0004744885,0.00003794583,0.0003522563,0.00007427937,0.0005815467],"category_scores_gemma":[0.0001943685,0.0003191308,0.0001936559,0.0005071328,0.00009692275,0.0001510541,0.0002431325,0.0001661387,0.00008124535],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.07110418,"about_ca_system_score_gemma":0.01558298,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001569411,"about_ca_topic_score_gemma":0.001075776,"domain_scores_codex":[0.9966828,0.00005865959,0.0004463597,0.0009150153,0.001029796,0.0008673247],"domain_scores_gemma":[0.9979786,0.0004811561,0.0001474483,0.0008069983,0.0001851142,0.0004007086],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2189756,0.007646007,0.1398528,0.004088153,0.01120686,0.002501465,0.0177683,0.09098915,0.002404806,0.001659092,0.03239895,0.4705089],"study_design_scores_gemma":[0.2854659,0.02341206,0.001687272,0.0003358521,0.0008683968,0.0000550033,0.0005060699,0.005382934,0.007415304,0.0002517837,0.6738424,0.0007770137],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908908,0.003715027,0.0001214614,0.0002416997,0.0006442418,0.003089224,0.0006769529,0.0001664774,0.0004541434],"genre_scores_gemma":[0.9869521,0.0003818549,0.001832689,0.0002875007,0.0004930144,0.001934256,0.0007704765,0.0001205604,0.007227581],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6414434,"threshold_uncertainty_score":0.9999261,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01781755912526684,"score_gpt":0.2833469322780211,"score_spread":0.2655293731527543,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}